Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Roche Holding AG | 1,581 |
| 2 | Merck and Co Inc | 648 |
| 3 | AbbVie Inc | 608 |
| 4 | Pfizer Inc | 375 |
| 5 | Novartis AG | 287 |
| 6 | Bayer AG | 284 |
| 7 | AstraZeneca PLC | 271 |
| 8 | Bristol Myers Squibb Co | 261 |
| 9 | Vertex Pharmaceuticals Inc | 233 |
| 10 | Daiichi Sankyo Co Ltd | 228 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 17,187 |
| 2 | A61K | Medicinal preparations | 15,395 |
| 3 | C07D | Heterocyclic compounds | 8,295 |
| 4 | C07K | Peptides | 6,282 |
| 5 | G01N | Investigating / analysing materials | 2,458 |
| 6 | C12N | Microorganisms, enzymes | 2,426 |
| 7 | C12Q | Measuring/testing involving enzymes | 1,185 |
| 8 | Y02A | Climate change adaptation | 1,140 |
| 9 | C07C | Acyclic and carbocyclic compounds | 692 |
| 10 | C07B | General methods of organic chemistry | 611 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| ANTICANCER COMBINATION THERAPY USING SUNITINIB MALATE | 2006 | Pfizer Inc | 39 |
| SUNITINIB HEMI-L-MALATE, POLYMORPHS AND PREPARATION THEREOF, POLYMORPHS OF RACEMIC SUNITINIB MALATE, COMPOSITINS CONTAINING SUNITINIB BASE AND MALIC ACID AND PREPARATION THEREOF | 2009 | Teva Pharmaceutical Industries Ltd | 26 |
| PROCESS FOR PREPARATION OF SUNITINIB MALATE AND SALTS THEREOF | 2012 | 12 | |
| NEW CRYSTAL FORM OF SUNITINIB MALATE | 2010 | Sandoz Group AG | 10 |
| Anticancer combination therapy using sunitinib malate | 2008 | Pfizer Inc | 10 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 281 |
| 2017 | 229 |
| 2018 | 225 |
| 2019 | 230 |
| 2020 | 191 |
| 2021 | 156 |
| 2022 | 172 |
| 2023 | 135 |
| 2024 | 125 |
| 2025 | 45 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Robert J. Motzer | Memorial Sloan Kettering Cancer Center | 136 |
| 2 | Brian I. Rini | Cleveland Clinic | 133 |
| 3 | Toni K. Choueiri | Dana-Farber Cancer Institute | 99 |
| 4 | Bernard Escudier | Institut Gustave Roussy | 69 |
| 5 | Camillo Porta | University of Pavia | 55 |
| 6 | Stéphane Oudard | Hôpital Européen Georges-Pompidou | 40 |
| 7 | Alain Ravaud | Hôpital Saint-André | 38 |
| 8 | Thomas Powles | Queen Mary University of London | 29 |
| 9 | David F. McDermott | Beth Israel Deaconess Medical Center | 28 |
| 10 | Patrick Schöffski | KU Leuven | 28 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma | 2007 | 5777 | Renal cell carcinoma treatment |
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma | 2018 | 4709 | Cancer Immunotherapy and Biomarkers |
| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | 2019 | 3454 | Cancer Immunotherapy and Biomarkers |
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | 2006 | 2612 | Gastric Cancer Management and Outcomes |
| Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | 2019 | 2583 | Pancreatic and Hepatic Oncology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular formula of Sutent?
Which organizations hold the most patents related to Sutent?
What are the major clinical research areas associated with Sutent?
Who are the leading researchers publishing on Sutent?
What is the patent landscape trend for Sutent-related compounds in recent years?